The North American Endoscopic Ultrasonography (EUS) Market is the industry that develops and provides advanced medical tools that combine a flexible camera tube (endoscope) with high-frequency ultrasound to create detailed, real-time images of the digestive tract and surrounding organs, like the pancreas and liver. This technology is critical for both finding diseases, such as precisely staging various cancers, and for guiding therapeutic procedures like collecting tissue samples with a needle (EUS-FNA). Driven by the growing need for minimally invasive procedures and the high rates of gastrointestinal conditions, this market focuses on continuous technological improvements to equipment like the imaging systems and specialized needles, ensuring better and safer patient diagnosis and treatment across the region.
Download PDF BrochureInquire Before Buying
The North American Endoscopic Ultrasonography (EUS) Market was valued at $XX billion in 2025, will reach $XX billion in 2026, and is projected to hit $XX billion by 2030, growing at a robust compound annual growth rate (CAGR) of XX%.
The global endoscopic ultrasonography market was valued at $1.28 billion in 2023, is estimated to reach $1.37 billion in 2024, and is projected to hit $1.93 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 7.1%
Drivers
The primary driver is the rising prevalence of gastrointestinal diseases and various cancers, including esophageal, gastric, and pancreatic cancers, across North America. This high disease burden fuels the critical demand for EUS as an advanced diagnostic tool for early detection, accurate staging of malignancies, and precise prognosis. EUS’s superior resolution over traditional imaging makes it indispensable in oncology, propelling its adoption across hospitals and specialty clinics.
A significant driver is the increasing preference for minimally invasive surgical and diagnostic procedures. EUS-guided techniques, such as fine-needle aspiration (FNA) and biopsy (FNB), offer reduced patient risk, shorter recovery times, and lower overall costs compared to traditional surgery. Furthermore, favorable reimbursement policies in the US and Canada for these advanced endoscopic procedures provide strong financial incentives for healthcare providers to adopt and utilize EUS technology.
North America’s well-established, technologically advanced healthcare infrastructure and high R&D investment are key accelerators. Hospitals continuously prioritize investment in technologically advanced EUS devices and expand their dedicated units to improve diagnostic accuracy and treatment outcomes. This is supported by substantial funding, grants, and strategic initiatives from governments and other organizations to bring cutting-edge medical innovations to market.
Restraints
A major restraint is the inherently high cost associated with EUS procedures and the sophisticated equipment itself. The expenses related to acquiring, maintaining, and upgrading advanced endoscopic ultrasound systems, probes, and specialized needles, combined with high overhead costs, can strain hospital budgets and limit the widespread adoption of EUS, particularly in smaller healthcare facilities and clinics.
The EUS market growth is significantly restrained by the scarcity of qualified and trained endoscopists and skilled professionals. EUS is an operator-dependent procedure that demands a high degree of technical expertise, precision, and extensive clinical experience for accurate diagnosis and effective therapeutic intervention. This shortage of specialized human capital restricts the full utilization of advanced EUS technology and slows down overall market penetration.
Concerns regarding patient safety, specifically the inherent risk of viral and bacterial infections during endoscopic procedures, act as a restraint. The complexity of properly cleaning and reprocessing reusable endoscopes and equipment necessitates strict sterilization protocols. Any perceived or actual failure in these processes raises patient safety issues, can lead to product recalls, and increases regulatory scrutiny, which can negatively impact market confidence.
Opportunities
Significant opportunities lie in the expansion of therapeutic and interventional EUS applications beyond just diagnostics. This includes the development of specialized EUS-guided procedures for drug delivery, tumor ablation, and advanced tissue acquisition techniques like EUS-FNB for core tissue samples. These developments allow EUS to become a more versatile and definitive tool for targeted treatment and personalized medicine.
The continuous development of advanced components, such as flexible miniature coaxial cables for enhanced image clarity and customizable, single-use EUS needles, presents a major opportunity. These innovations improve the safety, efficiency, and comfort of EUS. The market is also poised for growth through the development of hybrid systems that integrate EUS with other imaging modalities, expanding its use in areas like gastroenterology and pulmonology.
The growing role of Ambulatory Surgery Centers (ASCs) and specialty clinics offers a promising opportunity. ASCs are increasingly adopting EUS due to their cost-effectiveness and favorable reimbursement rates for outpatient procedures. This shift from traditional inpatient hospital settings broadens the access to and utilization of EUS procedures, driving demand for both capital equipment and consumable accessories like EUS needles.
Challenges
A key challenge is the technical complexity of EUS systems and the lack of universal standardization across different platforms and procedures. Integrating EUS devices into existing clinical workflows can be difficult, often requiring specialized infrastructure and extensive training. Overcoming this technical hurdle through greater user-friendliness and standardized protocols is crucial for broader, consistent clinical adoption.
While EUS is highly effective, the significant initial investment required for equipment and the high procedural cost remain a challenge for widespread adoption, particularly in cost-sensitive markets. Convincing healthcare systems of the long-term, superior diagnostic and therapeutic value of EUS over cheaper, less invasive, or alternative imaging modalities requires robust clinical and economic evidence to justify the high expenditure.
The market faces the challenge of continuous, rapid technological innovation amidst fierce competition among key market players. Companies must constantly invest in R&D to launch new, superior products—such as enhanced needles or AI-integrated systems—to stay competitive. Simultaneously, they must navigate complex global supply chains and regulatory environments to ensure new products meet the highest standards of safety and efficacy.
Role of AI
Artificial Intelligence plays a transformative role by integrating with EUS to enhance diagnostic accuracy and procedural efficiency. AI algorithms, particularly Convolutional Neural Networks (CNNs), are trained to quickly analyze EUS images in real-time, helping to identify complex lesions like Gastrointestinal Stromal Tumors (GISTs) and differentiate pancreatic cystic lesions with higher sensitivity and specificity than human experts alone.
AI is vital for providing intraprocedural guidance, which is critical for precision EUS-guided interventions like FNA/FNB. AI models offer real-time visualization and highlight areas of concern, ensuring more accurate needle placement and reducing human error. This automation helps streamline complex protocols, offloading cognitive strain on endoscopists and improving overall procedural throughput and consistency.
The integration of AI technology can significantly benefit the training of new endoscopists by offering guided visualization and objective performance feedback. Furthermore, AI is being applied to optimize workflow by integrating EUS data with other patient records for personalized treatment planning and facilitating rapid on-site evaluation of tissue samples, such as in Rapid On-Site Evaluation (ROSE) of biopsies.
Latest Trends
The most prominent procedural trend is the surging adoption and technological focus on EUS-guided fine-needle biopsy (EUS-FNB) over the older fine-needle aspiration (EUS-FNA). FNB is favored for its ability to obtain core tissue samples, which offer superior histological yield for definitive cancer diagnosis and genetic analysis. Manufacturers are responding by launching next-generation FNB needles with enhanced tips and flexibility.
A key technological trend is the convergence of EUS with advanced imaging modalities. This includes the growing clinical use of EUS-elastography, which assesses tissue stiffness to help distinguish between benign and malignant lesions, and contrast-enhanced EUS (CE-EUS) for better tissue characterization. These advancements significantly improve the diagnostic capabilities of the EUS platform, making it a more comprehensive tool.
The market is seeing a clear trend towards the full integration of EUS systems with digital technologies, including AI, CAD systems, and potentially robotic assistance. The goal is to create ‘smart’ endoscopy systems that offer real-time, AI-assisted diagnosis and automated workflows. The use of single-use, disposable endoscope components and accessories is also trending strongly due to heightened infection control demands.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=19121066